Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ATA3219
Evidence Based Cataract Study Group
Lupus Nephritis
1 trial -
Allogeneic (MSC's) Application to the Burn Wounds
United Therapeutics Europe Ltd
Skin Burn Degree Second
1 trial -
An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination with Itraconazole Capsules in Healthy Adult Female and Male Participants
AstraZeneca AB
Chronic obstructive pulmonary disease
1 trial -
An adaptive, randomized, double-blind, single-center, placebo-controlled first-in-human study evaluating safety, tolerability and exposure of single and multiple ascending doses of Lactobacillus expressing CXCL12 administered topically to experimentally induced skin wounds
Lacuna Pharma Pty Ltd
Wound healing
1 trial -
An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)
ViiV Healthcare Pty Ltd
HIV Infections
1 trial -
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaftor film coated tablets 150 mg of Sun Pharmaceutical Industries Ltd, India with Kalydeco (Ivacaftor) 150 mg film-coated tablets, Marketing Authorisation Holder: Vertex Pharmaceuticals (Ireland) Limited Unit 49, Block F2, Northwood Court, Santry, Dublin 9, D09 T665, Ireland, in healthy adult, human subjects under fed condition.
Lacuna Pharma Pty Ltd
Cystic Fibrosis
1 trial -
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
Lacuna Pharma Pty Ltd
Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis
1 trial -
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.
Lacuna Pharma Pty Ltd
ulcerative colitis
1 trial -
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fed condition.
Lacuna Pharma Pty Ltd
ulcerative colitis
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 160 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subject
Lacuna Pharma Pty Ltd
Prostate cancer
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 80 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subjects
Lacuna Pharma Pty Ltd
Prostate cancer
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarithromycin tablets 500 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Clarithromycin 500 mg coated tablets Manufactured by: Sanofi Medley Pharmaceuticals Ltd. Brazilian Industry, in healthy adult, human subjects under fasting condition.
Lacuna Pharma Pty Ltd
Infectious diseases
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITY® (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguariúna Administrative Building -SP CNPJ 60.397.775/
Lacuna Pharma Pty Ltd
cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)
1 trial -
An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)
Disc Medicine
High grade serous ovarian cancer
1 trial -
An open label, randomized, single dose, two-sequence, two-treatment, four-period, fully replicate, cross-over pharmacokinetic study comparing Alverine citrate/Simeticone 60 mg/300 mg soft capsules to Meteospasmyl 60 mg/300 mg soft capsules in healthy male and female subjects under fed conditions.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a bioavailability study in healthy subjects)
1 trial -
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette® lozenge 4 mg in healthy adults who use cigarettes
Swedish Orphan Biovitrum Pty Ltd
Nicotine use
1 trial -
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
Arsenic trioxide
Teva Pharma GmbH
Chronic Myelogenous Leukemia
1 trial -
Autologous Bone Marrow-derived Mononuclear Cells
Regeneron Ireland Designated Activity Company (DAC)
Congenital Heart Disease
1 trial -
Autologous Engineered Urethral Construct
United Therapeutics Europe Ltd
Urologic Diseases
1 trial -
Autologous Human Schwann Cell
United Therapeutics Europe Ltd
Peripheral Nerve Injury
1 trial -
Autologous Natural Killer Cell Therapy
Hospital Authority, Hong Kong
Hepatocellular Carcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources